EP0684823A4 - Antagonistes des recepteurs de fibrinogene. - Google Patents

Antagonistes des recepteurs de fibrinogene.

Info

Publication number
EP0684823A4
EP0684823A4 EP94909745A EP94909745A EP0684823A4 EP 0684823 A4 EP0684823 A4 EP 0684823A4 EP 94909745 A EP94909745 A EP 94909745A EP 94909745 A EP94909745 A EP 94909745A EP 0684823 A4 EP0684823 A4 EP 0684823A4
Authority
EP
European Patent Office
Prior art keywords
fibrinogenic
receptor antagonists
antagonists
receptor
fibrinogenic receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94909745A
Other languages
German (de)
English (en)
Other versions
EP0684823A1 (fr
Inventor
David Alan Claremon
John J Baldwin
Nigel Liverton
Ben Askew
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0684823A1 publication Critical patent/EP0684823A1/fr
Publication of EP0684823A4 publication Critical patent/EP0684823A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
EP94909745A 1993-02-22 1994-02-22 Antagonistes des recepteurs de fibrinogene. Withdrawn EP0684823A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2051793A 1993-02-22 1993-02-22
PCT/US1994/001881 WO1994018981A1 (fr) 1993-02-22 1994-02-22 Antagonistes des recepteurs de fibrinogene
US20517 1996-06-28

Publications (2)

Publication Number Publication Date
EP0684823A1 EP0684823A1 (fr) 1995-12-06
EP0684823A4 true EP0684823A4 (fr) 1997-07-09

Family

ID=21799049

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94909745A Withdrawn EP0684823A4 (fr) 1993-02-22 1994-02-22 Antagonistes des recepteurs de fibrinogene.

Country Status (15)

Country Link
EP (1) EP0684823A4 (fr)
JP (1) JP3173792B2 (fr)
KR (1) KR960700722A (fr)
CN (1) CN1118139A (fr)
AU (1) AU680240B2 (fr)
BG (1) BG99863A (fr)
CA (1) CA2155123A1 (fr)
CZ (1) CZ210895A3 (fr)
FI (1) FI953916A7 (fr)
HU (1) HUT71796A (fr)
NO (1) NO953270L (fr)
NZ (1) NZ262664A (fr)
PL (1) PL310386A1 (fr)
SK (1) SK102495A3 (fr)
WO (1) WO1994018981A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5494921A (en) * 1994-09-16 1996-02-27 Merck & Co., Inc. Fibrinogen receptor antagonists
ZA963391B (en) * 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
CZ293323B6 (cs) * 1995-08-30 2004-04-14 G. D. Searle & Co. Meta-guanidinové, močovinové, thiomočovinové nebo azacyklické deriváty aminobenzoové kyseliny jako antagonisty integrinů
US6100423A (en) * 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
WO1997011940A1 (fr) 1995-09-29 1997-04-03 Eli Lilly And Company Composes spiro comme inhibiteurs de l'agregation de plaquettes dependante du fibrinogene
AU1345697A (en) * 1995-12-22 1997-07-17 Du Pont Merck Pharmaceutical Company, The Novel integrin receptor antagonists
WO1997035579A1 (fr) * 1996-03-27 1997-10-02 Merck & Co., Inc. Procede d'inhibition de la formation de caillots
CN1478472A (zh) * 1996-07-25 2004-03-03 ¸ 细胞粘连抑制剂
US5900414A (en) * 1996-08-29 1999-05-04 Merck & Co., Inc. Methods for administering integrin receptor antagonists
DE19653647A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
JP2001512439A (ja) * 1997-02-06 2001-08-21 メルク エンド カンパニー インコーポレーテッド 線維素原受容体拮抗薬プロドラッグ
WO1998043962A1 (fr) * 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Promedicaments heterocycliques inhibiteurs d'integrine
US6303625B1 (en) * 1998-07-27 2001-10-16 Ortho-Mcneil Pharmaceutical, Inc. Triazolopyridines for the treatment of thrombosis disorders
CA2382755A1 (fr) * 1999-07-28 2001-02-01 Aventis Pharmaceuticals Products Inc. Composes d'oxoazaheterocyclyle substitue
AU2003297431A1 (en) * 2002-12-20 2004-07-22 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
US20100035756A1 (en) * 2006-07-12 2010-02-11 Syngenta Limited Triazolophyridine derivatives as herbicides
JP2011516498A (ja) 2008-04-04 2011-05-26 ギリアード サイエンシーズ， インコーポレイテッド ステアロイル−ＣｏＡデサチュラーゼの阻害剤として使用するためのトリアゾロピリジノン誘導体
WO2010096722A1 (fr) * 2009-02-20 2010-08-26 Takeda Pharmaceutical Company Limited 3-oxo-2,3-dihydro-[1,2,4]triazolo[4, 3-a]pyridines utilisées comme inhibiteurs de l'époxyde hydrolase soluble (eh soluble)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0381033A1 (fr) * 1989-01-31 1990-08-08 F. Hoffmann-La Roche Ag Amides d'acides carboxyliques et amides sulfoniques

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8913011D0 (en) * 1989-06-06 1989-07-26 Wellcome Found Anticonvulsant pyrazines
US5166154A (en) * 1989-10-17 1992-11-24 Boehringer Ingelheim Pharmaceuticals, Inc. Imidazo[1,2-a]piperazines
US5278161A (en) * 1990-06-28 1994-01-11 Hoffmann-La Roche Inc. Amino acid derivatives useful as renin inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0381033A1 (fr) * 1989-01-31 1990-08-08 F. Hoffmann-La Roche Ag Amides d'acides carboxyliques et amides sulfoniques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
B.C. ASKEW ET AL.: "Non-peptide glycoprotein IIb/IIIa inhibitors.", BIOORG. MED. CHEM. LETT., vol. 5, no. 5, 1995, pages 475 - 480, XP000670733 *
See also references of WO9418981A1 *

Also Published As

Publication number Publication date
EP0684823A1 (fr) 1995-12-06
NO953270D0 (no) 1995-08-21
FI953916A0 (fi) 1995-08-21
HU9502028D0 (en) 1995-09-28
FI953916L (fi) 1995-08-21
FI953916A7 (fi) 1995-08-21
HUT71796A (en) 1996-02-28
JPH08507072A (ja) 1996-07-30
NZ262664A (en) 1997-04-24
KR960700722A (ko) 1996-02-24
NO953270L (no) 1995-10-19
CZ210895A3 (en) 1996-02-14
SK102495A3 (en) 1997-01-08
BG99863A (bg) 1996-02-29
CN1118139A (zh) 1996-03-06
PL310386A1 (en) 1995-12-11
WO1994018981A1 (fr) 1994-09-01
AU680240B2 (en) 1997-07-24
JP3173792B2 (ja) 2001-06-04
AU6246594A (en) 1994-09-14
CA2155123A1 (fr) 1994-09-01

Similar Documents

Publication Publication Date Title
BR9407933A (pt) Antagonistas de receptores de endotelina
DZ2320A1 (fr) Antagonistes de récepteurs de vitronectine.
NO972016D0 (no) Indolyl-Y-reseptorantagonister
EP0810994A4 (fr) Antagonistes des recepteurs de fibrinogene
TR199801594A3 (tr) CCR-3 reseptör antagonistleri.
FI920217L (fi) Angiotensin ii receptor blockerande 2,3,6-substituerade kinazolinoner.
EP0986385A4 (fr) Antagonistes de gonadoliberine
FI914533L (fi) Fibrinogenreceptorantagonister.
TR199600212A2 (tr) Endotelin-reseptörü-antagonistleri.
FI922143A7 (fi) Muscarinreceptorantagonister.
EP0885205A4 (fr) Antagonistes des recepteurs de fibrinogenes
DZ1773A1 (fr) Antagonistes de récepteurs d'endothéline.
EP0866705A4 (fr) Antagonistes du recepteur de fibrinogene
FI914532A7 (fi) Fibrinogenreceptorantagonister.
FI922344L (fi) Muscarinreceptorantagonister.
TR199600359A2 (tr) Adezyon reseptörü antagonistleri.
FI960516A7 (fi) Substituoituja bifenyylisulfonamidiendoteliiniantagonisteja
FI953916A7 (fi) Fibrinogeenireseptoriantagonisteja
DK0906294T3 (da) Benzoxazinon-dopamin D4-receptor-antagonister
TR199501389A2 (tr) Adesyon reseptörü antagonistleri (karsitlari).
BR9507220A (pt) Antagonistas de receptores de endotelina
DZ2322A1 (fr) Antagonistes de récepteurs de vitronectine.
DE69204920D1 (de) Angiotensin-II-Antagoniste.
DE69636597D1 (de) Endothelin rezeptor antagonisten
ZA963391B (en) Isoxazoline fibrinogen receptor antagonists.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950922

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970522

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19981014

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020122